Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31334748 | 1.00 | BTK (0.53) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL26506949 | 1.00 | BTK (0.53) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL8272629 | 0.92 | BTK (0.59) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL31460585 | 0.92 | BTK (0.59) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14375819 | 0.92 | BTK (0.59) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14349354 | 0.92 | BTK (0.59) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL982187 | 0.90 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL982185 | 0.90 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL31333338 | 0.86 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL31334269 | 0.86 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-12 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023147531-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| CN-105001165-B | Substituted diaminopyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-111094255-A | Compound having cyclic structure | 第一三共株式会社 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885KDM1A 1633/4885MAOB 2833/4885 |
| US-20230322695-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN5 | BTK 76/4885KDM1A 2466/4885MAOB 1357/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | BTK 76/4885KDM1A 2466/4885MAOB 1357/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885KDM1A 1633/4885MAOB 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.